Read full comments from Walter Klemp, Chairman and Chief Executive Officer of Moleculin, on the completion of the End of Phase 2 meeting with the FDA for the Phase 1B/2 clinical trial for Annamycin in #AcuteMyeloidLeukemia: https://bit.ly/3S1aOPs
Moleculin Biotech, Inc.
Pharmaceutical Manufacturing
Houston, Texas 2,644 followers
Groundbreaking Cancer Therapies
About us
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.
- Website
-
http://www.moleculin.com
External link for Moleculin Biotech, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Houston, Texas
- Type
- Public Company
- Founded
- 2006
Locations
-
Primary
Get directions
5300 Memorial Dr
Suite 950
Houston, Texas 77007, US
Employees at Moleculin Biotech, Inc.
Updates
-
Moleculin today announced the completion of its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 trial of Annamycin in combination with Cytarabine for treatment of AML as both first line therapy and for subjects who are refractory to or relapsed after induction therapy. The Company expects to report outcomes from the EOP2 meeting upon receipt of official minutes from FDA which is expected by the end of Q3 2024. For more information: https://bit.ly/3S1aOPs
-
Moleculin presented additional positive preliminary interim data from the ongoing Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of #AcuteMyeloidLeukemia at #EHA2024 and a KOL meeting with #AML experts. For poster details and certain slides from the KOL meeting: https://bit.ly/4bQpMQ1
-
Moleculin CEO Walter Klemp comments on the additional efficacy data from the ongoing Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of #AcuteMyeloidLeukemia: https://bit.ly/4bQpMQ1 #EHA2024
-
Moleculin today reported additional efficacy findings from the ongoing Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of #AcuteMyeloidLeukemia. Preliminary data was presented at the European Hematology Association (EHA) 2024 Hybrid Congress as well as a KOL meeting with leading AML experts. For more information: https://bit.ly/4bQpMQ1 #EHA2024
-
Join us today, June 12th at 12:00 PM ET for Moleculin's presentation at the Virtual Investor Lunch Break: The Moleculin Opportunity event. Register for the live webcast: https://bit.ly/4bVW7F1
-
Moleculin will present at the Virtual Investor Pitch Conference on Tuesday, June 18th at 3:00 PM ET. Register for the live webcast: https://bit.ly/3yZ7FZB
-
Don't miss the Virtual Investor Lunch Break: The Moleculin Opportunity event tomorrow, June 12th at 12:00 PM ET! Moleculin CEO Walter Klemp will provide a corporate overview in addition to a live investor Q&A. To register: https://bit.ly/3VinqT8
-
Moleculin CEO Walter Klemp will provide a corporate overview and business outlook as part of the Virtual Investor Lunch Break: The Moleculin Opportunity webcast on Wednesday, June 12th at 12:00 PM ET. An investor Q&A will follow the remarks, for more information: https://bit.ly/3VinqT8
-
Moleculin will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Wednesday, June 12, 2024 at 12:00 PM ET. Register for the live webcast: https://bit.ly/3VinqT8